Contingency Management Just Got a Hard Number: 117 Lives Saved Per 1,000 People, $6,850 a QALY

For three decades, the case for contingency management (CM) — the behavioral intervention that provides tangible rewards for biochemically verified abstinence — has been clinical-trial-strong and policy-implementation-weak. The Cochrane reviews, the meta-analyses, the original Higgins studies from the early 1990s: all consistent, all pointing the same direction. And yet, until 2025, the federal cap on annual CM incentives at $75 per patient effectively kept the modality out of routine Medicaid practice.

That gap is now closing. A 2026 cost-effectiveness modeling study — indexed alongside an AJP cohort analysis of CM and mortality — provides the cleanest economic numbers yet for CM in stimulant use disorder. A 12-week program prevents an estimated 117 deaths per 1,000 enrolled in the first year, with a net gain of 0.70 QALYs per person at an incremental cost of $6,850 compared to no treatment. A 24-week program prevents 153 deaths per 1,000 with a 0.81 QALY gain.

For context: $6,850 per QALY is well below conventional cost-effectiveness thresholds. Most U.S. health-policy literature uses $50,000 to $100,000 per QALY as the upper range for “high-value” interventions. CM for stimulant use disorder is roughly an order of magnitude better than that ceiling.

What changed in January 2025

The mechanistic barrier was the federal incentive cap. Under earlier OIG guidance, providers risked anti-kickback exposure if cumulative annual CM rewards exceeded $75 per patient — a number set when the underlying logic was about avoiding payments for referrals, not about evidence-based behavioral treatment. In January 2025, that ceiling was raised tenfold, to $750 per patient per year. This is the threshold researchers and clinicians have argued for years was needed to reach what the field calls “behaviorally relevant magnitude” — the dollar level at which the reinforcement actually shifts behavior in a sustained way.

The result, by 2026: CM is now operational in roughly five state Medicaid programs as a covered benefit, with two more in active rulemaking. Arizona is not yet on either list. That gap, against the backdrop of increasing stimulant-fentanyl polysubstance deaths and the state’s overdose trajectory, is one of the cleanest evidence-to-policy gaps in the 2026 addiction landscape.

What this means for treatment planning

For clinicians and program directors building 2026–2027 program plans:

• CM is now the most cost-effective stimulant-use-disorder intervention with a Cochrane-grade evidence base. Methamphetamine and cocaine use disorders still have no FDA-approved pharmacotherapy. CM is the closest thing the field has to a standard-of-care behavioral protocol.
• Polysubstance use is the rule, not the exception. The same patients enrolling in CM for stimulants are often candidates for MOUD (for concurrent OUD). Bundled-care programs — CM + buprenorphine + peer support — produce better retention than any single modality.
• Engagement infrastructure matters more than incentive design. The 12- vs. 24-week dose-response in the cost-effectiveness model is large. Programs that drop participants at week 8 lose much of the value. Reminder systems, transportation supports, and the kind of warm-handoff navigation that bridges between modalities are not “wraparound” services — they are dose-determining services.

Why this matters for people in recovery

If you or someone you love is using methamphetamine, cocaine, or other stimulants and looking for treatment options, contingency management is one of the most evidence-supported approaches available. It is not a moral judgment, it is not “paying people to do what they should be doing anyway,” and the 2026 evidence is now unambiguous: programs that use it correctly save lives at a fraction of the cost of standard medical care. Ask your state Medicaid plan, your treatment provider, or your county behavioral-health department whether CM is available. If it isn’t, that is a question worth carrying into the public SOR comment cycle this summer.

For navigation in Arizona, dial 211 or use Rize Recovery’s free find-help tool. If you’re in crisis, call or text 988.

---

Rize Recovery does not provide medical advice. Treatment decisions should be made with a qualified clinician.